Skip to main content

Table 1 Clinical, histological and molecular parameters of 181 node-negative breast cancer patients

From: C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Parameter Number of patients (%)
Tumour size  
   T1 118 (65.2)
   T2 54 (29.8)
   T3/4 9 (5.0)
Age (years)  
   <40 14 (7.7)
   40–55 46 (25.4)
   >55 121 (66.9)
Histopathological grading  
   G1 5 (2.8)
   G2 105 (58)
   G3 71 (39.2)
ER status  
   ER negative 64 (35.4)
   ER positive 115 (63.5)
   Unknown 2 (1.1)
PR status  
   PR negative 66 (36.5)
   PR positive 112 (61.9)
   Unknown 3 (1.7)
Oncogenes  
   C-myc nonamplified 142 (78.5)
   C-myc amplified 39 (21.5)
HER-2/neu nonamplified 126 (69.6)
HER-2/neu amplified 55 (30.4)
   C-myc and HER-2/neu coamplified 22 (12.2)
  1. ER, oestrogen receptor; PR, progesterone receptor.